Dr. med. Urs Hess
Low dose 2-chlorodeoxyadenosine given as a single subcutaneous injection in patients with hairy cell leukemia: a multicentre trial SAKK 32/95
Zenhäusern R, Tobler A, Leoncini L, Kovacsovic T, Bargetzi M, Hess U, Gratwohl A, Meyer-Monard S, Solenthaler M, Rufibach K, von Rohr A, Swiss Group for Clinical Cancer Research (SAKK). Low dose 2-chlorodeoxyadenosine given as a single subcutaneous injection in patients with hairy cell leukemia: a multicentre trial SAKK 32/95. Leukemia & lymphoma 2009; 50:133-6.
Jan 1, 2009Low dose 2-chlorodeoxyadenosine given as a single subcutaneous injection in patients with hairy cell leukemia: a multicentre trial SAKK 32/95
Jan 1, 2009Leukemia & lymphoma 2009; 50:133-6
Zenhäusern Reinhard, Tobler Andreas, Leoncini Leda, Kovacsovic Tibor, Bargetzi Mario J, Hess Urs, Gratwohl Alois, Meyer-Monard Sandrine, Solenthaler Max, Rufibach Kaspar, von Rohr Albert, Swiss Group for Clinical Cancer Research (SAKK)
The multicenter trial SAKK 37/95 of cladribine, cyclophosphamide and prednisone in the treatment of chronic lymphocytic leukemias and low-grade non-Hodgkin's lymphomas
Laurencet F, Zulian G, Plancherel C, Luthi J, Fey M, Cerny T, Hess U, Rufener B, Ballabeni P, Swiss Group for Clinical Research (SAKK). The multicenter trial SAKK 37/95 of cladribine, cyclophosphamide and prednisone in the treatment of chronic lymphocytic leukemias and low-grade non-Hodgkin's lymphomas. Acta haematologica 2007; 117:40-7.
Jan 1, 2007The multicenter trial SAKK 37/95 of cladribine, cyclophosphamide and prednisone in the treatment of chronic lymphocytic leukemias and low-grade non-Hodgkin's lymphomas
Jan 1, 2007Acta haematologica 2007; 117:40-7
Laurencet France, Zulian Gilbert B, Plancherel Catherine, Luthi Jean-Marc, Fey Martin, Cerny Thomas, Hess Urs, Rufener Beatrice, Ballabeni Pierluigi, Swiss Group for Clinical Research (SAKK)
[The plasma cell myeloma--molecular pathogenesis and target therapies]
Hess U. [The plasma cell myeloma--molecular pathogenesis and target therapies]. Ther Umsch 2006; 63:233-6.
Apr 1, 2006[The plasma cell myeloma--molecular pathogenesis and target therapies]
Apr 1, 2006Ther Umsch 2006; 63:233-6
Hess Urs
Polysomy 8 defines a clinico-cytogenetic entity representing a subset of myeloid hematologic malignancies associated with a poor prognosis: report on a cohort of 12 patients and review of 105 published cases
Beyer V, van Melle G, Schmidt P, Schanz U, Laurencet F, Chapuis B, Hess U, Hitz F, Gregor M, Pugin P, Tobler A, Solenthaler M, Bougeon-Mamin S, Cabrol C, Parlier V, Mühlematter D, Jotterand M. Polysomy 8 defines a clinico-cytogenetic entity representing a subset of myeloid hematologic malignancies associated with a poor prognosis: report on a cohort of 12 patients and review of 105 published cases. Cancer genetics and cytogenetics 2005; 160:97-119.
Jul 15, 2005Polysomy 8 defines a clinico-cytogenetic entity representing a subset of myeloid hematologic malignancies associated with a poor prognosis: report on a cohort of 12 patients and review of 105 published cases
Jul 15, 2005Cancer genetics and cytogenetics 2005; 160:97-119
Beyer Valérie, van Melle Guy, Schmidt Pierre-Michel, Schanz Urs, Laurencet France, Chapuis Bernard, Hess Urs, Hitz Felicitas, Gregor Michael, Pugin Paul, Tobler Andreas, Solenthaler Max, Bougeon-Mamin Sandrine, Cabrol Christine, Parlier Valérie, Mühlematter Dominique, Jotterand Martine
Proposal of a morphologic bone marrow response score for imatinib mesylate treatment in chronic myelogenous leukemia
Lugli A, Tichelli A, Von Juergensonn S, Mach-Pascual S, Borisch B, Tinguely M, Hawle H, Korte W, Hess U, Passweg J, Gratwohl A, Cogliatti S, Ebnoether M, Dirnhofer S. Proposal of a morphologic bone marrow response score for imatinib mesylate treatment in chronic myelogenous leukemia. Hum Pathol 2005; 36:91-100.
Jan 1, 2005Proposal of a morphologic bone marrow response score for imatinib mesylate treatment in chronic myelogenous leukemia
Jan 1, 2005Hum Pathol 2005; 36:91-100
Lugli Alessandro, Tichelli André, Von Juergensonn Silke, Mach-Pascual Sara, Borisch Bettina, Tinguely Marianne, Hawle Hanne, Korte Wolfgang, Hess Urs, Passweg Jakob, Gratwohl Alois, Cogliatti Sergio B., Ebnoether Monika, Dirnhofer Stephan
Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule
Ghielmini M, Vorobiof D, Bargetzi M, Lohri A, Helg C, Kovacsovics T, Stupp R, Zucca E, Hess U, Peccatori F, Martinelli G, Betticher D, Fey M, Waltzer U, Hummerjohann J, Pichert G, Cogliatti S, Schmitz S, Cerny T. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004; 103:4416-23.
Jun 15, 2004Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule
Jun 15, 2004Blood 2004; 103:4416-23
Ghielmini Michele, Vorobiof Daniel, Bargetzi Mario, Lohri Andreas, Helg Claudine, Kovacsovics Tibor, Stupp Roger, Zucca Emanuele, Hess Urs, Peccatori Fedro, Martinelli Giovanni, Betticher Daniel C, Fey Martin F, Waltzer Ursula, Hummerjohann Jörg, Pichert Gabriella, Cogliatti Sergio B, Schmitz Shu-Fang Hsu, Cerny Thomas